Ascentage Pharma Group International (6855.HK)
HKD 48.6
(-1.02%)
HKD 48.6
(-1.02%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 2.5 Billion CNY | -11.66% |
| 2022 | 2.83 Billion CNY | -3.73% |
| 2021 | 2.94 Billion CNY | 69.84% |
| 2020 | 1.73 Billion CNY | 43.65% |
| 2019 | 1.2 Billion CNY | -1.98% |
| 2018 | 1.22 Billion CNY | 111.36% |
| 2017 | 581.66 Million CNY | -1.97% |
| 2016 | 593.34 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q2 | 3.1 Billion CNY | 0.0% |
| 2023 Q4 | 2.5 Billion CNY | 0.0% |
| 2023 FY | 2.5 Billion CNY | -11.66% |
| 2023 Q2 | 2.91 Billion CNY | 0.0% |
| 2022 Q2 | 3.03 Billion CNY | 0.0% |
| 2022 Q4 | 2.83 Billion CNY | 0.0% |
| 2022 FY | 2.83 Billion CNY | -3.73% |
| 2021 Q4 | 2.94 Billion CNY | 0.0% |
| 2021 FY | 2.94 Billion CNY | 69.84% |
| 2021 Q2 | 2.4 Billion CNY | 0.0% |
| 2020 FY | 1.73 Billion CNY | 43.65% |
| 2020 Q2 | 1.1 Billion CNY | 0.0% |
| 2020 Q4 | 1.73 Billion CNY | 0.0% |
| 2019 Q2 | 1.07 Billion CNY | 0.0% |
| 2019 FY | 1.2 Billion CNY | -1.98% |
| 2019 Q4 | 1.2 Billion CNY | 0.0% |
| 2018 Q4 | 1.22 Billion CNY | 0.0% |
| 2018 FY | 1.22 Billion CNY | 111.36% |
| 2017 FY | 581.66 Million CNY | -1.97% |
| 2016 FY | 593.34 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 409.99 Million HKD | -509.864% |
| CK Life Sciences Int'l., (Holdings) Inc. | 11.24 Billion HKD | 77.769% |